Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats

British Journal of Pharmacology

Volumn 150, Issue 7, 2007, Pages 851-861

  Louhelainen, M ^a   Vahtola, E ^a   Kaheinen, P ^b   Leskinen, H ^c   Merasto, S ^a   Kyto V ^d   Finckenberg, P ^b   Colucci, W S ^e   Levijoki, J ^b   Pollesello, P ^b   Haikala, H ^b   Mervaala, E M A ^a,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; Calcium (cellular); Hypertension; Inotropic agents; Remodeling

Indexed keywords

CALCIUM; INOTROPIC AGENT; LEVOSIMENDAN; MARKER; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIET; DISEASE SEVERITY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG MECHANISM; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERTENSION; LOW DRUG DOSE; MALE; NICK END LABELING; NONHUMAN; NORADRENALIN URINE LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; SYSTOLIC DYSFUNCTION;

ANIMALS; APOPTOSIS; ATRIAL NATRIURETIC FACTOR; HYDRAZONES; HYPERTENSION; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; OSTEOPONTIN; PYRIDAZINES; RATS; RATS, INBRED DAHL; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 34047235534     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707157     Document Type: Article

References (46)

1. Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H (2002). Levosimendan increases L-type Ca2+ current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 435: 27-33.
2. Akao M, Ohler A, O'Rourke B, Marban E (2001). Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 88: 1267-1275.
3. Ardehali H, O'Rourke B (2005). Mitochondrial KATP channels in cell survival and death. J Mol Cell Cardiol 39: 7-16.
4. Bers DM (2002). Cardiac excitation-contraction coupling. Nature 415: 198-204.
5. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U et al. (1997). Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharm Exp Ther 280: 277-283.
6. del Monte F, Hajjar RJ (2003). Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546: 49-61.
7. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA et al. (2005). Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis. Implication in heart failure. Circulation 111: 2469-2476.
8. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG et al. (1995). Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113.
9. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K et al. (2002). Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196-202.
10. Giordano FJ (2005). Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500-508.
11. Grover GJ, Garlid KD (2000). ATP-sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol 32: 677-695.
12. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB (1995). Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27: 1859-1866.
13. Hasenfuss G, Pieske B (2002). Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34: 951-969.
14. Herbert RA, Hailey JR, Seely JC, Shackelford CC, Jokinen MP, Wolf JC et al. (2002). Nomenclature. In: Haschek WM, Rousseaux CG, Wallig MA (eds). Handbook of Toxicologic Pathology. Academic Press: San Diego, pp 157-167.
15. Ikeda S, Hamada M, Qu P, Hiasa G, Hashida H, Shigematsu Y et al. (2002). Relationship between cardiomyocyte cell death and cardiac function during hypertensive cardiac remodelling in Dahl rats. Clin Sci 102: 329-335.
16. Innes CA, Wagstaff AJ (2003). Levosimendan. A review of its use in the management of acute decompensated heart failure. Drugs 63: 2651-2671.
17. Jaburek M, Costa ADT, Burton JR, Costa CL, Garlid KD (2006). Mitochondrial PKCε and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res 99: 878-883.
18. Jessup M, Brozena S (2003). Medical progress. Heart failure. N Engl J Med 348: 2007-2018.
19. Kaheinen P, Pollesello P, Levijoki J, Haikala H (2001). Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37: 367-374.
20. Kang PM, Izumo S (2000). Apoptosis and heart failure. A critical review of the literature. Circ Res 86: 1107-1113.
21. Kivikko M, Lehtonen L, Colucci WS (2003). Sustained hemodynamic effects of intravenous levosimendan. Circulation 107: 81-86.
22. Kihara Y, Sasayama S (1997). Transition from compensatory hypertrophy to dilated failing left ventricle in Dahl-Iwai salt-sensitive rats. Am J Hypertens 10: 78S-82S.
23. Klotz S, Hay I, Zhang G, Maurer M, Wang J, Burkhoff D (2006). Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension 47: 901-911.
24. Kopustinskiene DM, Pollesello P, Saris NE (2001). Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 428: 311-314.
25. Kopustinskiene DM, Pollesello P, Saris NE (2004). Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 68: 807-812.
26. Kytö V, Saraste A, Saukko P, Henn V, Pulkki K, Vuorinen T et al. (2004). Apoptotic cardiomyocyte death in fatal myocarditis. Am J Cardiol 94: 746-750.
27. Levijoki J, Pollesello P, Kaheinen P, Haikala H (2001). Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol 419: 243-248.
28. Maytin M, Colucci WS (2005). Cardioprotection: a new paradigm in the acute management of acute heart failure syndromes. Am J Cardiol 96: 26G-31G.
29. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ et al. (1996). Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335: 1182-1189.
30. Noguchi T, Kihara Y, Begin KJ, Gorga JA, Palmiter KA, LeWinter MM et al. (2003). Altered myocardial thin-filament function in the failing Dahl salt-sensitive rat heart. Circulation 107: 630-635.
31. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA et al. (1997). Apoptosis in the failing human heart. N Engl J Med 336: 1131-1141.
32. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S et al. (2004). Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93: 1309-1312.
33. Rapp JP, Dene H (1985). Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. Hypertension 7: 340-349.
34. Seki S, Nagai M, Takeda H, Onodera T, Okazaki F, Taniguchi M et al. (2003). Impaired Ca2+ handling in perfused hypertrophic hearts from Dahl salt-sensitive rats. Hypertens Res 26: 643-653.
35. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J et al. (2000). Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102: 2222-2227.
36. Szewczyk A, Marbán E (1999). Mitochondria: a new target for K+ channel openers? Trends Pharmacol Sci 20: 157-161.
37. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I et al. (2004). The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486: 67-74.
38. Takahashi R, Endoh M (2005). Dual regulation ofmyofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 145: 1143-1152.
39. Tojo A, Onozato MT, Kobayashi N, Goto A, Matsuoka H, Fujita T (2002). Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 40: 834-839.
40. Virag L, Hala O, Marton A, Varro A, Papp JG (1996). Cardiac electrophysiological effects of levosimendan, an new calcium sensitizer. Gen Pharmacol 27: 551-556.
41. von Harsdorf R, Li PF, Dietz R (1999). Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99: 2934-2941.
42. Walder RY, Morgan DA, Haynes WG, Sigmund RD, McClain AM, Stokes JB et al. (1996). Genetic characterization of the 'New' Harlan Sprague Dawley Dahl salt-sensitive rats. Hypertension 27: 546-551.
43. Yano M, Ikeda Y, Matsuzaki M (2005). Altered intracellular Ca2+ handling in heart failure. J Clin Invest 115: 556-564.
44. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997a). The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383.
45. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997b). Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333: 249-259.
46. Yoneda T, Kihara Y, Ohkusa T, Iwanaga Y, Inagaki K, Takeuchi Y et al. (2001). Calcium handling and sarcoplasmic-reticular protein functions during heart-failure transition in ventricular myocardium from rats with hypertension. Life Sci 70: 143-157.